# LYPD1

## Overview
LYPD1 is a gene that encodes the protein LY6/PLAUR domain containing 1, which is a member of the Ly6/uPAR superfamily. This protein is characterized by the presence of a LU domain, which typically features a three-fingered structural motif stabilized by disulfide bridges. LYPD1 is predicted to be a glycosylphosphatidylinositol (GPI)-anchored protein, allowing it to associate with the plasma membrane and participate in cell signaling processes (Masuda2018Inhibition; Fu2023Identification). The protein is involved in various biological functions, including odontoblast differentiation and neuronal development, and is implicated in several signaling pathways such as BMP, Wnt, and TGFβ (Loughner2016Organization; Fu2023Identification). LYPD1's expression and interactions are significant in both developmental and pathological contexts, including its roles in cancer and angiogenesis (Song2024A; Masuda2018Inhibition).

## Structure
The LYPD1 gene encodes a protein that is part of the Ly6/uPAR superfamily, characterized by the presence of a LU domain. This domain typically features a three-fingered structural motif formed by disulfide bridges connecting conserved cysteine residues (Loughner2016Organization; Masuda2018Inhibition). The primary structure of LYPD1 includes an amino-terminal signal peptide, indicating that it is a secreted protein. Following this, the protein contains an Ly-6 domain, which is marked by a conserved pattern of cysteine residues forming up to five disulfide bridges (Egerod2007GPR39).

LYPD1 is predicted to be a glycosylphosphatidylinositol (GPI)-anchored protein, allowing it to associate with the plasma membrane, which is crucial for its role in cell signaling (Masuda2018Inhibition; Fu2023Identification). The protein may exist in multiple isoforms due to alternative splicing, although specific isoforms are not detailed in the available context (Fu2023Identification).

Post-translational modifications of LYPD1 likely include glycosylation and the formation of disulfide bonds, which are common in the Ly6/uPAR family (Loughner2016Organization). The protein's structure and modifications suggest its involvement in various signaling pathways, including those related to odontoblast differentiation and angiogenesis (Sakamoto2020Heartderived; Fu2023Identification).

## Function
The LYPD1 gene encodes a GPI-anchored protein that plays a crucial role in odontoblast differentiation during tooth development. This protein is essential for the differentiation of dental mesenchymal cells into odontoblasts, primarily through the bone morphogenetic protein (BMP) signaling pathway. LYPD1 influences the phosphorylation of Smad1/5/8, a critical step in the BMP/Smad signaling pathway, which is necessary for the expression of odontoblast marker genes such as Panx3, Alpl, and Dspp (Fu2023Identification).

LYPD1 is localized in lipid rafts, which are microdomains in the plasma membrane that facilitate various signaling pathways, including BMP, Wnt, and TGFβ. The presence of LYPD1 in these lipid rafts is crucial for its function, as it associates with bone morphogenetic protein receptors (BMPR) and induces the necessary phosphorylation events for odontoblast differentiation (Fu2023Identification).

In addition to its role in tooth development, LYPD1 is expressed in the nervous system, where it may influence neuronal development and synaptic function. It is expressed in postmitotic central and peripheral neurons, including subpopulations of motor and sensory neurons, and plays a significant role in regulating anxiety by modulating neuronal nicotinic receptors (Loughner2016Organization).

## Clinical Significance
Alterations in the expression of the LYPD1 gene have been implicated in various diseases and conditions. In bladder cancer (BLCA), LYPD1 is significantly downregulated in cancerous cells compared to normal cells. This downregulation is associated with increased tumor growth, proliferation, migration, and invasion, suggesting that LYPD1 acts as a tumor suppressor in this context. Overexpression of LYPD1 in BLCA cells has been shown to reduce these malignant characteristics, indicating its potential as a therapeutic target and prognostic marker for bladder cancer (Song2024A).

In hepatocellular carcinoma (HCC), LYPD1 is identified as an oncogenic factor. The ALKBH5 gene, which acts as a tumor suppressor in HCC, inhibits LYPD1 expression through m6A-guided epigenetic mechanisms. This suppression of LYPD1 by ALKBH5 is associated with reduced malignancy in HCC, highlighting the complex role of LYPD1 in different cancer types (Chen2020ALKBH5).

LYPD1 also plays a role in endothelial network formation. In cardiac fibroblasts, LYPD1 expression inhibits vascular network formation, which could impact the development of bioengineered tissues and angiogenesis. Knockdown of LYPD1 in these cells has been shown to restore endothelial network formation, suggesting its involvement in anti-angiogenic processes (Masuda2018Inhibition).

## Interactions
LYPD1, a GPI-anchored protein, is involved in several interactions that are crucial for its function in cellular processes. It is localized in lipid rafts, which are membrane microdomains that facilitate various signaling pathways. LYPD1 interacts with bone morphogenetic protein (BMP) receptors within these lipid rafts, leading to the phosphorylation of Smad1/5/8, a key step in the BMP signaling pathway essential for odontoblast differentiation (Fu2023Identification). This interaction underscores the importance of LYPD1 in tooth development, as it modulates the BMP2-Smad1/5/8 pathway, which is critical for odontoblast differentiation (Fu2023Identification).

In the context of hepatocellular carcinoma (HCC), LYPD1 mRNA stability is regulated through interactions with the m6A effector protein IGF2BP1. IGF2BP1 binds to LYPD1 mRNA, promoting its stability. This interaction is crucial for maintaining LYPD1 expression levels, as knockdown of IGF2BP1 significantly reduces LYPD1 expression (Chen2020ALKBH5). These interactions highlight the role of LYPD1 in both developmental and pathological contexts, where it participates in complex regulatory networks involving protein and nucleic acid interactions.


## References


[1. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

[2. (Masuda2018Inhibition) Shinako Masuda, Katsuhisa Matsuura, and Tatsuya Shimizu. Inhibition of lypd1 is critical for endothelial network formation in bioengineered tissue with human cardiac fibroblasts. Biomaterials, 166:109–121, June 2018. URL: http://dx.doi.org/10.1016/j.biomaterials.2018.03.002, doi:10.1016/j.biomaterials.2018.03.002. This article has 19 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.biomaterials.2018.03.002)

[3. (Sakamoto2020Heartderived) Satoru Sakamoto, Katsuhisa Matsuura, Shinako Masuda, Nobuhisa Hagiwara, and Tatsuya Shimizu. Heart-derived fibroblasts express lypd-1 and negatively regulate angiogenesis in rat. Regenerative Therapy, 15:27–33, December 2020. URL: http://dx.doi.org/10.1016/j.reth.2020.03.010, doi:10.1016/j.reth.2020.03.010. This article has 4 citations.](https://doi.org/10.1016/j.reth.2020.03.010)

[4. (Song2024A) Zhen Song, Shikai Gui, Shuaiyun Xiao, Xuepeng Rao, Na Cong, Huanhuan Deng, Zhaojun Yu, and Tao Zeng. A novel anoikis-related gene signature identifies lypd1 as a novel therapy target for bladder cancer. Scientific Reports, February 2024. URL: http://dx.doi.org/10.1038/s41598-024-53272-0, doi:10.1038/s41598-024-53272-0. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-53272-0)

[5. (Egerod2007GPR39) Kristoffer L. Egerod, Birgitte Holst, Pia S. Petersen, Jacob B. Hansen, Jan Mulder, Tomas Hökfelt, and Thue W. Schwartz. Gpr39 splice variants versus antisense gene lypd1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Molecular Endocrinology, 21(7):1685–1698, July 2007. URL: http://dx.doi.org/10.1210/me.2007-0055, doi:10.1210/me.2007-0055. This article has 65 citations.](https://doi.org/10.1210/me.2007-0055)

[6. (Chen2020ALKBH5) Yunhao Chen, Yanchun Zhao, Junru Chen, Chuanhui Peng, Yanpeng Zhang, Rongliang Tong, Qiyang Cheng, Beng Yang, Xiaode Feng, Yuejie Lu, Haiyang Xie, Lin Zhou, Jian Wu, and Shusen Zheng. Alkbh5 suppresses malignancy of hepatocellular carcinoma via m6a-guided epigenetic inhibition of lypd1. Molecular Cancer, August 2020. URL: http://dx.doi.org/10.1186/s12943-020-01239-w, doi:10.1186/s12943-020-01239-w. This article has 204 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s12943-020-01239-w)

[7. (Fu2023Identification) Yao Fu, Kanako Miyazaki, Yuta Chiba, Keita Funada, Tomomi Yuta, Tian Tian, Kanji Mizuta, Jumpei Kawahara, Ling Zhang, Daniel Martin, Tsutomu Iwamoto, Ichiro Takahashi, Satoshi Fukumoto, and Keigo Yoshizaki. Identification of gpi-anchored protein lypd1 as an essential factor for odontoblast differentiation in tooth development. Journal of Biological Chemistry, 299(5):104638, May 2023. URL: http://dx.doi.org/10.1016/j.jbc.2023.104638, doi:10.1016/j.jbc.2023.104638. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jbc.2023.104638)